Log in to search using one of your social media accounts:

 

Doctors may be ordering too many coronary interventions
Physicians may be ordering too many percutaneous coronary intervention procedures...Read more on AuntMinnie.comRelated Reading: FFR-CT algorithm guides management of revascularization Use criteria cut unnecessary heart interventions NIH study ties soft plaque on CT to cardiac risk factors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 16, 2018 Category: Radiology Source Type: news

Localized cooling of the heart limits damage caused by a heart attack
(Eindhoven University of Technology) Researchers from Eindhoven University of Technology and the Catharina hospital in Eindhoven have succeeded in the localized cooling of the heart during a heart attack, a world first. By cooling part of the heart prior to and following angioplasty, the cardiologists believe that the damage from a heart attack can be limited. On 11 January cardiologist Luuk Otterspoor received his doctorate at Eindhoven University of Technology for this study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 12, 2018 Category: International Medicine & Public Health Source Type: news

When VA Outsources PCI, Some Patients Lose (CME/CE)
(MedPage Today) -- Survival disadvantage seen with angioplasties at non-VA centers -- but not with CABG (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - January 3, 2018 Category: Surgery Source Type: news

FDA Again Warns on Balloon Angioplasty for Neurologic Disorders
(MedPage Today) -- Says transvascular autonomic modulation is off-label and dangerous (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 26, 2017 Category: Primary Care Source Type: news

Better treatment, not more spending, saves heart attack patients, study finds
(Michigan Medicine - University of Michigan) A long-term look at heart attack care and spending in America in the 21st Century shows more survival, more spending, and more variation between hospitals on both scores. And while spending on rapid angioplasty appears to be paying off, a lot of the dollars spent in the six months after a heart attack aren't making a difference in the long-term death rate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2017 Category: International Medicine & Public Health Source Type: news

Bringing Robotics into the Cath Lab to Protect Physicians
Percutaneous Coronary Intervention (PCI, or angioplasty with stent) is a common procedure used to treat patients with obstructive coronary artery disease, with an estimated 600,000 procedures performed annually in the United States. PCI has a low risk of complications for patients, but that's not the case for clinicians. Patients receive a dose of radiation during a PCI procedure, which takes anywhere from 30 minutes to a few hours. Interventional cardiologists and cardiac catheterization laboratory personnel are exposed to ionizing radiation all day, every day. Protective measures, such as radiation safety caps,...
Source: MDDI - December 15, 2017 Category: Medical Devices Authors: Heather R. Johnson Tags: Medical Device Business Source Type: news

Percutaneous coronary intervention is a well-justified option also in severe coronary artery disease
(University of Eastern Finland) The treatment of left main coronary artery disease by percutaneous coronary intervention is associated with a smaller risk of severe cardiovascular events than coronary artery bypass grafting in the weeks following surgery. A meta-analysis of several trials and nearly 5,000 patients revealed no differences in mortality between the two treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news

7 medtech stories we missed this week: Dec. 8, 2017
[Image from unsplash.com]From Minimus Spine’s European distribution deal to Stimwave receiving FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Minimus Spine inks EU distribution deal Minimus Spine announced in a Dec. 4 press release that it has signed its first European distribution deal with Italian company Moss and has completed its first commercial order. Moss has exclusive distribution rights to distribute in Italy, Germany, Switzerland and the U.K. 2. Elanix, Dermacon sign wound management development deal Elanix Biotechnologies and Dermacon...
Source: Mass Device - December 8, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiac Assist Devices Cardiovascular Diagnostics Food & Drug Administration (FDA) Hospital Care Pain Management Regulatory/Compliance Cagent Vascular CSA Medical Inc. Dermacon Elanix Life Spine Inc. MedTech Minimus Spin Source Type: news

Robocath adds $2m for new neurovascular platform
Medical robotics startup Robocath said today that it added about $2 million (€1.7 million) to the more than $5 million it raised earlier this year, taking its total to $7.5 million in funding this year. Rouen, France-based Robocath, which is developing the R-One robotic platform for coronary angioplasty, is pursuing CE Mark approval in the European Union for the system. R-One is expected to hit the market in Europe and the Middle East next year, the company said. Get the full story at our sister site, The Robot Report. The post Robocath adds $2m for new neurovascular platform appeared first on MassDevic...
Source: Mass Device - December 6, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Robotics Wall Street Beat Robocath Source Type: news

FOXTROT ™ NC PTCA Balloon Catheter Gains Regulatory Approval in Argentina
(Source: Microport News Release)
Source: Microport News Release - November 24, 2017 Category: Medical Devices Source Type: news

When to Stent in Stable CAD? That Is (Still) the Question When to Stent in Stable CAD? That Is (Still) the Question
Drs Harrington, Maron, and Patel discuss the ORBITA trial, which compared coronary stenting with sham percutaneous coronary intervention for angina relief. Why did ORBITA cause so much buzz?theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 22, 2017 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Perioperative Aspirin Might Benefit Patients with Prior PCI
Perioperative aspirin seems beneficial for high-risk patients undergoing noncardiac surgery who've previously undergone percutaneous coronary intervention (PCI), according to a subanalysis from the POISE... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 14, 2017 Category: Primary Care Source Type: news

Aspirin can prevent heart attacks after noncardiac surgery in patients with prior PCI
(University of Alberta Faculty of Medicine& Dentistry) A Canadian-led study has found that perioperative aspirin can prevent heart-related complications after major noncardiac surgery in patients with previous percutaneous coronary intervention (PCI) such as an angioplasty or stent. The study found that for every 1,000 patients with PCI, giving them aspirin at the time of noncardiac surgery would prevent 59 heart attacks and cause eight major bleeding events. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news

Interview with Yusuke Yoshikawa, MD
Dr. Yoshikawa discusses his study, just published in Circulation, titled "Validating Utility of DAPT Score in a Large Pooled Cohort from Three Japanese PCI Studies," and he comments on how the Japanese population differs from western patients in terms of bleeding and ischemic event rates. (posted in collaboration with TCROSS NEWS) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - November 10, 2017 Category: Cardiology Source Type: news

Study: PCI Appears No Better Than Sham Procedure in Patients with Stable Angina (FREE)
By Kelly Young Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Percutaneous coronary intervention (PCI) didn't improve exercise time relative to a sham procedure in patients with stable angina and severe coronary stenosis. Findings from the ORBITA study were published in the Lancet and presented at the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 3, 2017 Category: Primary Care Source Type: news

Are Artery-Opening Stents for Chest Pain a Waste of Time?
Source: HealthDay Related MedlinePlus Pages: Angina, Angioplasty, Coronary Artery Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 2, 2017 Category: Consumer Health News Source Type: news

Analysis Shows Better Health Outcomes and Cost Effectiveness for Coronary Intervention Using Abbott's Fractional Flow Reserve (FFR) Diagnostic in Patients with Stable Coronary Artery Disease
After three years, patients who underwent FFR-guided percutaneous coronary intervention (PCI) in combination with medical therapy had significantly fewer major adverse cardiac events compared to patients who received medical therapy alone (Source: Abbott.com)
Source: Abbott.com - November 2, 2017 Category: Pharmaceuticals Source Type: news

Complex CTO-PCI: The Japanese Approach
This 20 minute video shows a complex CTO case, in which an RCA obstruction, complicated by a sharp bend and tortuous anatomy, was revascularized using both the antegrade and retrograde approaches, facilitated by IVUS and biplane angiographic imaging. The operator is Dr. Etsuo Tsuchikane; the case was broadcast live during the Japanese CTO Club course in June 2017. (posted in collaboration with TCROSS NEWS) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - October 31, 2017 Category: Cardiology Source Type: news

Cordis Comes Back for Another Stent
Cordis is getting back into the coronary stent game. The company, which is now owned by Cardinal Health, landed exclusive rights to sell Medinol's coronary stent portfolio in the U.S. Milpitas, CA-based Cordis is already selling Medinol's NIRxcell cobalt-chromium bare-metal stent and, assuming FDA approves Medinol's EluNIR drug-eluting stent (DES), Cordis will distribute it as well. Medinol is based in Israel. In addition to the Medinol agreement, Cordis recently launched the Tryton Side Branch Stent and two percutaneous transluminal coronary angioplasty (PTCA) balloon catheters. The Medinol agreement, along with the ...
Source: MDDI - October 31, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Should patients with cardiogenic shock receive culprit lesion only PCI or multivessel PCI?
(Cardiovascular Research Foundation) Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2017 Category: International Medicine & Public Health Source Type: news

SCAI launches educational initiative as nation shifts to value-based healthcare
(Society for Cardiovascular Angiography and Interventions) The Society for Cardiovascular Angiography and Interventions announced today the launch of TRAnsition for VALUE, a multi-faceted educational initiative supported by Medtronic, to inform cardiologists, hospital administrators, and cath lab staff about the benefits of expanding the adoption of transradial (wrist access) percutaneous coronary intervention (PCI) in the US. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2017 Category: International Medicine & Public Health Source Type: news

FDA clears expansion of CeloNova ’s nano-coated coronary stent trial
CeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding. The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day DAPT following percutaneous coronary intervention. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears expansion of CeloNova’s nano-coated coronary stent trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 26, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Stents Vascular CeloNova BioSciences Source Type: news

Registry data examines oral anticoagulant use in women, adverse events after PCI discharge
(American College of Cardiology) Data from the American College of Cardiology's National Cardiovascular Data Registry was the source of several published studies in recent months, including a study on predicting 30-day readmission rates for patients undergoing percutaneous coronary intervention and a study that found women were less likely to use oral anticoagulants to treat atrial fibrillation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 5, 2017 Category: International Medicine & Public Health Source Type: news

This cardiac catheter uses light and ultrasound to measure plaques
[Image from Marcu Lab/UC Davis]Researchers at the University of California at Davis combined ultrasound with light into a catheter probe to view the tiny arteries of the heart. The device uses intravascular ultrasound and fluorescence lifetime imaging (FLIm) to retrieve structural and biochemical information about plaque in the arteries to help predict heart attacks more reliably, according to the researchers. Currently, doctors use angioplasty to view blood vessels in constricted regions. A contrasting agent has to be injected to be able to view the vessels in an X-ray, but sometimes an angioplasty could miss dangerous pl...
Source: Mass Device - October 4, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Cardiovascular Catheters Diagnostics Research & Development heart disease MedTech University of California at Davis Source Type: news

Andreas Roland Gruentzig, the Man Andreas Roland Gruentzig, the Man
A fascinating profile of Andreas Gruentzig, the renowned cardiologist who first developed balloon angioplasty, and is considered the father of modern-day percutaneous coronary intervention.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

7 medtech stories we missed this week: Sept. 22, 2017
[Image from unsplash.com]From the FDA’s clearance of Covalon’s film-drape to Bioventus launching its study, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Covalon’s MediClear OTC surgical film-drape Covalon announced in a Sept. 21 press release that the FDA has cleared its MediClear PreOp to market in U.S. hospitals, clinic and directly to patients without a prescription. The MediClear PreOp is a breathable, transparent, self-adhesive, silicone barrier film-drape that can conform to a patient’s skin at a planned incision or insertion si...
Source: Mass Device - September 22, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Business/Financial News Diagnostics Food & Drug Administration (FDA) Laboratory Instruments/Laboratory Supplies mHealth (Mobile Health) Research & Development Vascular Bioventus LLC Contego Medical Covalon Technologies Getinge Guerbe Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 20, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. The 10 largest medical device companies in the world Mergers & acquisitions continue to change the medical device landscape, as reflected in Medical Design & Outsourcing’s new Big 100 list. We pulled financial reg...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Reva Medical ’s Fantom bioresorbable, drug-eluting vascular scaffold succeeds at 6 months
As some companies have worked to improve drug-eluting stents by making them bioresorbable, some voices in the coronary intervention space have expressed concern over the rates of late stent thrombosis and repeat percutaneous coronary intervention seen with the devices. In a study published in the September issue of JACC: Cardiovascular Intervention, Reva Medical‘s (ASX:RVA) Fantom coronary bioresorbable vascular scaffold succeeded after six months. The device was designed to address challenges like strut size and expansion capacity, the researchers wrote. Get the full story at our sister site, Drug Delivery...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Pharmaceuticals Wall Street Beat Abbott Reva Medical Inc. Source Type: news

Surmodics Announces Global Approvals of .014 & #226; �? Low-Profile PTA Balloon Dilation Catheter
The company received FDA 510(k) and CE Mark clearance EDEN PRAIRIE, Minn. - Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) and CE Mark clearance for its .014” low-profile percutaneous transluminal angioplasty (PTA) balloon dilation catheter, designed for peripheral angioplasty procedures. The company is making this product...This story is related to the following:Catheters (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - September 19, 2017 Category: Medical Devices Source Type: news

SurModics wins FDA, CE Mark for low-profile PTA balloon dilation cath
SurModics (NSDQ:SRDX) said today it won both FDA 510(k) clearance and CE Mark clearance in the European Union for its 0.014″ low-profile percutaneous translumioal angioplasty balloon dilation catheter with plans to launch the device in the coming months. The newly launched PTA ballon catheter comes equipped with the company’s Serene hydrophilic coating, allowing for low friction and particulates, the Eden Prairie, Minn.-based company said. SurModics said the clearance and coming launch of the low-profile PTA cath is a continuation of the company’s strategy to supply whole-product vascular solutions. ...
Source: Mass Device - September 18, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Catheters Food & Drug Administration (FDA) Regulatory/Compliance Vascular SurModics Inc. Source Type: news

7 medtech stories we missed this week: Sept. 15, 2017
[Image from unsplash.com]From Acera Surgical and Telos Medical’s partnership to Xtant Medical’s 510(k) clearance, here are seven medtech stories we missed this week but thought were still worth a mention. 1. Acera Surgical partners with Telos Medical for Restrata wound matrix trial Telos Partners announced in a Sept. 14 press release that Acera Surgical has chosen Telos to lead its Restrata wound matrix study. The study will surgery the clinical outcomes of Restrata treatments for diabetic foot ulcers and test for effectiveness and safety. Restrata is a fully synthetic wound matrix that is FDA-cleared for ...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Business/Financial News Clinical Trials Dental Diagnostics Food & Drug Administration (FDA) Regulatory/Compliance Surgical Acera Surgical Contego Medical Fresenius MedTech OBP Medical Pinnacle Sciences Plusoptix Telos Source Type: news

Firefighter ™ PTCA Balloon Catheter Receives Regulatory Approval in South Korea
(Source: Microport News Release)
Source: Microport News Release - September 12, 2017 Category: Medical Devices Source Type: news

Study examines use of systolic blood pressure at time of primary percutaneous coronary intervention
(Society for Cardiovascular Angiography and Interventions) Researchers have led a retrospective single-center study examining simple hemodynamic parameters obtained at the time of cardiac catheterization to predict in-hospital mortality following ST-elevation myocardial infarction (STEMI). Current 30-day mortality rates for patients with STEMI range from 2.5% to 10%, and 10.5%-24% of those patients require mechanical hemodynamic support. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2017 Category: International Medicine & Public Health Source Type: news

Japan approves Medtronic ’s In.Pact Admiral drug-coated balloon
Medtronic (NYSE:MDT) said today that its In.Pact Admiral drug-coated balloon won approval from the Japanese Ministry of Health, Labour and Welfar for the treatment of peripheral artery disease in the upper leg. Before the medtech giant can begin commercialization of its drug-device combination product, it must gain reimbursement from the Japanese regulatory body, Medtronic said. “The In.Pact Admiral DCB has demonstrated superior one-year clinical outcomes in Japan and across Medtronic In.Pact SFA clinical trials, providing patients with an improved restoration of blood flow and reduced need for additional revasc...
Source: Mass Device - September 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Vascular Wall Street Beat Medtronic Source Type: news

BLS Crews in Paris Detect Atypical STEMI via 12-Lead ECG
By Jonathan Gonzva, MD; Laure Alhanati, MD; Stéphane Dubourdieu, MD; Daniel Jost, MD; Hugues Lefort, MD; Benoît Frattini, MD & Jean-Pierre Tourtier, MD A 61-year-old man calls the Paris Fire Brigade dispatch center with a complaint of dental pain. He reports feeling pain in the jaw for the past 35 minutes, which he says now extends to the armpits. He also reports that he experienced the same feeling the day before. The patient's age and hyperlipidemia were his only cardiovascular risk factors with atorvastatine and budesonide as the usual treatments. The physician stationed at the dispatch cen...
Source: JEMS Patient Care - September 7, 2017 Category: Emergency Medicine Tags: International Cardiac & Resuscitation Columns Patient Care Source Type: news

Rethinking dual antiplatelet guidelines in acute coronary syndrome? (CHANGE-DAPT)
(European Society of Cardiology) New research presented at ESC Congress today1 suggests that for acute coronary syndrome (ACS) patients who require percutaneous coronary intervention (PCI), treatment according to contemporary guidelines for dual anti-platelet therapy (DAPT) could be less preferable than sticking to older guidelines. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2017 Category: International Medicine & Public Health Source Type: news

LSUHealthNO research award to improve heart attack recovery
(Louisiana State University Health Sciences Center) LSU Health New Orleans will receive $735,000 over two years to study the effectiveness of the first patented drug-eluting guidewire in preventing a complication that can occur following treatment of heart attacks with angioplasty. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 28, 2017 Category: Biology Source Type: news

Ra Medical CEO Irwin aims for Feb 2018 IPO
In May, Ra Medical received a nod from the FDA for its Dabra arteriosclerosis laser, clearing it for use in the US. It was a decision the company had been waiting on for approximately 3 years, CEO Dean Irwin told MassDevice.com in an interview, and signaled a significant shift forward. “In 2014, we submitted to the FDA, and here in 2017, just on May 24th, we received the go ahead to begin marketing in the United States,” Irwin said. Ra Medical won CE Mark approval in the European Union last October, giving the company time to launch in the region, which it’s been operating in for several mo...
Source: Mass Device - August 24, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Regulatory/Compliance Ra Medical Source Type: news

Firefighter ™ PTCA Balloon Catheter Gains Regulatory Approval in Argentina
(Source: Microport News Release)
Source: Microport News Release - August 17, 2017 Category: Medical Devices Source Type: news

Angioplasty Outcomes Almost Equal Among Hospitals
Title: Angioplasty Outcomes Almost Equal Among HospitalsCategory: Health NewsCreated: 8/7/2017 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - August 8, 2017 Category: Cardiology Source Type: news

Angioplasty outcomes almost equal among hospitals
Patients who undergo percutaneous coronary intervention have similar outcomes at different hospitals, researchers said. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 8, 2017 Category: Consumer Health News Source Type: news

Angioplasty Outcomes Almost Equal Among Hospitals
'Safety-net' facilities do as well as other hospitals with the artery procedure, researchers find (Source: WebMD Health)
Source: WebMD Health - August 7, 2017 Category: Consumer Health News Source Type: news

Angioplasty Outcomes Almost Equal Among Hospitals
'Safety-net' facilities do as well as other hospitals with the artery procedure, researchers find Source: HealthDay Related MedlinePlus Pages: Angioplasty, Health Disparities, Health Facilities (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 7, 2017 Category: Consumer Health News Source Type: news

Angioplasty Outcomes Almost Equal Among Hospitals
MONDAY, Aug. 7, 2017 -- Patients who have an artery-opening procedure called percutaneous coronary intervention (PCI) have similar outcomes whether they're treated at so-called safety-net or non-safety-net hospitals, researchers say. Safety-net... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 7, 2017 Category: General Medicine Source Type: news

U.S. Hospitals Set Record for Fast Heart Attack Care
There's never been a better time to be treated for a heart attack. U.S. hospitals have set a record for how quickly they open blocked arteries, averaging under one hour for the first time since these results have been tracked. More than 93 percent of patients now have their arteries opened within the recommended 90 minutes of arrival. "Things have definitely improved" from a decade ago, when less than half of heart attack patients were treated that fast, said Dr. Fred Masoudi, a University of Colorado cardiologist who led a recent report examining response times. It's based on records from about 85 percent of U.S...
Source: JEMS Patient Care - July 31, 2017 Category: Emergency Medicine Authors: Marilynn Marchione, Chief Medical Writer, Associated Press Tags: Patient Care Cardiac & Resuscitation News Source Type: news

U.S. Hospitals Set Record for Fast Heart Attack Care
There's never been a better time to be treated for a heart attack. U.S. hospitals have set a record for how quickly they open blocked arteries, averaging under one hour for the first time since these results have been tracked. More than 93 percent of patients now have their arteries opened within the recommended 90 minutes of arrival. "Things have definitely improved" from a decade ago, when less than half of heart attack patients were treated that fast, said Dr. Fred Masoudi, a University of Colorado cardiologist who led a recent report examining response times. It's based on records from about 85 percent of U.S...
Source: JEMS: Journal of Emergency Medical Services News - July 31, 2017 Category: Emergency Medicine Authors: Marilynn Marchione, Chief Medical Writer, Associated Press Tags: Patient Care Cardiac & Resuscitation News Source Type: news

Medtronic's Evolut PRO Now Available in Europe
Medtronic has announced that its latest transcatheter aortic valve, the CoreValve Evolut PRO, has received the CE mark and is now available for use in Europe. In a reversal of the usual order of device approvals, FDA approval pre-dated the CE Mark - the Evolut PRO was first given an FDA okay back in March. This new generation valve utilizes a biocompatible porcine outer wrap that increases surface contact and sealing to reduce paravavular leaks (PVL). Another major improvement over earlier iterations was the reduced necessity for permanent pacemaker implantation: only 10% in this cohort. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 31, 2017 Category: Cardiology Source Type: news

Clinical Trial to Study If 3-Months of DAPT is Safe After XIENCE Stent
The study, called XIENCE Short DAPT, will evaluate if 3 months of DAPT is non-inferior to the current standard of 12 months after implantation with a XIENCE stent for patients who are at high risk of bleeding. The study will enroll approximately 2,000 patients at 100 sites in the U.S. and Asia. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 26, 2017 Category: Cardiology Source Type: news

Blacks and Whites Have Similar Outcomes After PCI Blacks and Whites Have Similar Outcomes After PCI
A study designed to look for differing outcomes when black and white U.S. veterans undergo percutaneous coronary intervention (PCI) instead found no differences once confounding factors were taken into account.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 25, 2017 Category: Intensive Care Tags: Family Medicine/Primary Care News Source Type: news

Roxwood Medical Announces Agreement with Abbott for Distribution of Products in U.S.
REDWOOD CITY, Calif., July 25, 2017 -- (Healthcare Sales & Marketing Network) -- Roxwood Medical Inc., a leading provider of advanced cardiovascular specialty catheters, today announced it has entered into an exclusive agreement with Abbott for distributi... Devices, Interventional, Cardiology, Distribution Roxwood Medical, Abbott, CenterCross, Percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 25, 2017 Category: Pharmaceuticals Source Type: news